Mistral (Dienogest, Ethinylestradiol)

Mistral, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal contraception and related menstrual disorders.

• Contraception: provides reliable prevention of pregnancy in women of reproductive age.
• Menstrual cycle regulation: helps to achieve more predictable menstrual bleeding patterns.
• Acne management: can improve acne associated with androgen excess in women.

• Mistral combines dienogest, a progestogenic agent that binds to progesterone receptors, with ethinylestradiol, a synthetic estrogen that activates estrogen receptors. The progestogen suppresses the luteinizing hormone surge, preventing ovulation, while the estrogen stabilizes the endometrium and modifies cervical mucus, creating an environment unfavorable for sperm penetration and implantation.

Oral administration of Mistral may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects

• Nausea: mild to moderate stomach upset, often transient.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: swelling or discomfort of the breasts.
• Breakthrough bleeding: spotting between periods.
• Weight fluctuation: mild changes in body weight.
• Mood changes: irritability or mild mood swings.

Serious or Rare Side Effects

• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Hepatic dysfunction: jaundice or abnormal liver enzymes.
• Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Mistral, clinicians should evaluate individual risk factors and contraindications.

• Contraindications: avoid use in women with a history of thromboembolic disease, estrogen‑dependent tumors, or active liver disease.
• Smoking: do not prescribe to women over 35 who smoke, due to increased cardiovascular risk.
• Cardiovascular risk: assess hypertension, diabetes, or hyperlipidaemia before initiation.
• Pregnancy and lactation: discontinue if pregnancy is confirmed; safety during breastfeeding is not established.
• Drug interactions: review concomitant medications that may affect clotting or hormone metabolism.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Mistral can interact with several medicines that alter hormone metabolism or increase clotting risk.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): may reduce efficacy of anticoagulation, increasing thrombosis risk.
• Hepatic enzyme inducers (e.g., rifampicin, carbamazepine): can markedly lower plasma levels of ethinylestradiol and dienogest, reducing contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): may increase the risk of bleeding when combined with hormonal therapy.
• Antifungal agents (e.g., ketoconazole): can raise hormone concentrations, potentially enhancing side‑effects.
• Antiretrovirals (e.g., protease inhibitors): may alter hormone metabolism; monitor for reduced contraceptive reliability.